nodes	percent_of_prediction	percent_of_DWPC	metapath
Salbutamol—ADRB2—prostate cancer	0.281	0.646	CbGaD
Salbutamol—CYP3A4—prostate cancer	0.154	0.354	CbGaD
Salbutamol—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.065	0.207	CbGbCtD
Salbutamol—CYP3A4—Bicalutamide—prostate cancer	0.0341	0.109	CbGbCtD
Salbutamol—CYP3A4—Estramustine—prostate cancer	0.0317	0.101	CbGbCtD
Salbutamol—CYP3A4—Flutamide—prostate cancer	0.0283	0.09	CbGbCtD
Salbutamol—CYP3A4—Abiraterone—prostate cancer	0.0283	0.09	CbGbCtD
Salbutamol—CYP3A4—Cabazitaxel—prostate cancer	0.0209	0.0666	CbGbCtD
Salbutamol—CYP3A4—Estrone—prostate cancer	0.0205	0.0651	CbGbCtD
Salbutamol—CYP3A4—Ethinyl Estradiol—prostate cancer	0.0182	0.058	CbGbCtD
Salbutamol—CYP3A4—Conjugated Estrogens—prostate cancer	0.0134	0.0426	CbGbCtD
Salbutamol—CYP3A4—Mitoxantrone—prostate cancer	0.0122	0.0387	CbGbCtD
Salbutamol—CYP3A4—Estradiol—prostate cancer	0.0117	0.0374	CbGbCtD
Salbutamol—CYP3A4—Prednisone—prostate cancer	0.0101	0.0321	CbGbCtD
Salbutamol—CYP3A4—Etoposide—prostate cancer	0.00767	0.0244	CbGbCtD
Salbutamol—CYP3A4—Docetaxel—prostate cancer	0.00702	0.0223	CbGbCtD
Salbutamol—CYP3A4—Doxorubicin—prostate cancer	0.00523	0.0166	CbGbCtD
Salbutamol—Pirbuterol—ADRB2—prostate cancer	0.000405	0.0861	CrCbGaD
Salbutamol—Levobunolol—ADRB2—prostate cancer	0.000361	0.0767	CrCbGaD
Salbutamol—Salmeterol—CYP3A5—prostate cancer	0.000355	0.0754	CrCbGaD
Salbutamol—Terbutaline—ADRB2—prostate cancer	0.00033	0.0701	CrCbGaD
Salbutamol—Isoetarine—ADRB2—prostate cancer	0.000318	0.0675	CrCbGaD
Salbutamol—Carteolol—ADRB2—prostate cancer	0.000307	0.0652	CrCbGaD
Salbutamol—Salmeterol—ADRB2—prostate cancer	0.00028	0.0596	CrCbGaD
Salbutamol—Nadolol—ADRB2—prostate cancer	0.000273	0.0581	CrCbGaD
Salbutamol—Norepinephrine—SLC22A3—prostate cancer	0.000267	0.0567	CrCbGaD
Salbutamol—Clenbuterol—ADRB2—prostate cancer	0.000264	0.0561	CrCbGaD
Salbutamol—Bupranolol—ADRB2—prostate cancer	0.000261	0.0555	CrCbGaD
Salbutamol—Clenbuterol—CYP1A1—prostate cancer	0.000226	0.0481	CrCbGaD
Salbutamol—Norepinephrine—SLC22A1—prostate cancer	0.000191	0.0407	CrCbGaD
Salbutamol—Epinephrine—SLC22A1—prostate cancer	0.000174	0.0369	CrCbGaD
Salbutamol—Salmeterol—CYP3A4—prostate cancer	0.000154	0.0327	CrCbGaD
Salbutamol—Isoprenaline—ADRB2—prostate cancer	0.000132	0.028	CrCbGaD
Salbutamol—Norepinephrine—ADRB2—prostate cancer	0.000122	0.026	CrCbGaD
Salbutamol—Isoprenaline—CYP1A1—prostate cancer	0.000113	0.024	CrCbGaD
Salbutamol—Epinephrine—ADRB2—prostate cancer	0.000111	0.0236	CrCbGaD
Salbutamol—Epinephrine—CYP3A4—prostate cancer	6.06e-05	0.0129	CrCbGaD
Salbutamol—Urethral disorder—Epirubicin—prostate cancer	4.56e-05	0.000218	CcSEcCtD
Salbutamol—Loss of consciousness—Prednisone—prostate cancer	4.55e-05	0.000218	CcSEcCtD
Salbutamol—Epistaxis—Doxorubicin—prostate cancer	4.52e-05	0.000216	CcSEcCtD
Salbutamol—Anorexia—Capecitabine—prostate cancer	4.52e-05	0.000216	CcSEcCtD
Salbutamol—Nausea—Estradiol—prostate cancer	4.51e-05	0.000216	CcSEcCtD
Salbutamol—Vomiting—Mitoxantrone—prostate cancer	4.5e-05	0.000215	CcSEcCtD
Salbutamol—Sinusitis—Doxorubicin—prostate cancer	4.49e-05	0.000215	CcSEcCtD
Salbutamol—Hypertension—Prednisone—prostate cancer	4.47e-05	0.000214	CcSEcCtD
Salbutamol—Rash—Mitoxantrone—prostate cancer	4.46e-05	0.000214	CcSEcCtD
Salbutamol—Dermatitis—Mitoxantrone—prostate cancer	4.46e-05	0.000213	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Docetaxel—prostate cancer	4.46e-05	0.000213	CcSEcCtD
Salbutamol—Headache—Mitoxantrone—prostate cancer	4.44e-05	0.000212	CcSEcCtD
Salbutamol—Hypotension—Capecitabine—prostate cancer	4.43e-05	0.000212	CcSEcCtD
Salbutamol—Insomnia—Docetaxel—prostate cancer	4.43e-05	0.000212	CcSEcCtD
Salbutamol—Myalgia—Prednisone—prostate cancer	4.4e-05	0.000211	CcSEcCtD
Salbutamol—Arthralgia—Prednisone—prostate cancer	4.4e-05	0.000211	CcSEcCtD
Salbutamol—Paraesthesia—Docetaxel—prostate cancer	4.4e-05	0.00021	CcSEcCtD
Salbutamol—Anxiety—Prednisone—prostate cancer	4.39e-05	0.00021	CcSEcCtD
Salbutamol—Dyspnoea—Docetaxel—prostate cancer	4.36e-05	0.000209	CcSEcCtD
Salbutamol—Somnolence—Docetaxel—prostate cancer	4.35e-05	0.000208	CcSEcCtD
Salbutamol—Discomfort—Prednisone—prostate cancer	4.35e-05	0.000208	CcSEcCtD
Salbutamol—Hypersensitivity—Etoposide—prostate cancer	4.34e-05	0.000208	CcSEcCtD
Salbutamol—Tinnitus—Epirubicin—prostate cancer	4.33e-05	0.000207	CcSEcCtD
Salbutamol—Haemoglobin—Doxorubicin—prostate cancer	4.32e-05	0.000207	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Capecitabine—prostate cancer	4.32e-05	0.000207	CcSEcCtD
Salbutamol—Cardiac disorder—Epirubicin—prostate cancer	4.31e-05	0.000206	CcSEcCtD
Salbutamol—Flushing—Epirubicin—prostate cancer	4.31e-05	0.000206	CcSEcCtD
Salbutamol—Rhinitis—Doxorubicin—prostate cancer	4.31e-05	0.000206	CcSEcCtD
Salbutamol—Dyspepsia—Docetaxel—prostate cancer	4.31e-05	0.000206	CcSEcCtD
Salbutamol—Haemorrhage—Doxorubicin—prostate cancer	4.3e-05	0.000206	CcSEcCtD
Salbutamol—Insomnia—Capecitabine—prostate cancer	4.29e-05	0.000205	CcSEcCtD
Salbutamol—Hypoaesthesia—Doxorubicin—prostate cancer	4.28e-05	0.000205	CcSEcCtD
Salbutamol—Pharyngitis—Doxorubicin—prostate cancer	4.27e-05	0.000204	CcSEcCtD
Salbutamol—Paraesthesia—Capecitabine—prostate cancer	4.26e-05	0.000204	CcSEcCtD
Salbutamol—Decreased appetite—Docetaxel—prostate cancer	4.26e-05	0.000204	CcSEcCtD
Salbutamol—Urinary tract disorder—Doxorubicin—prostate cancer	4.25e-05	0.000203	CcSEcCtD
Salbutamol—Gastrointestinal disorder—Docetaxel—prostate cancer	4.23e-05	0.000202	CcSEcCtD
Salbutamol—Asthenia—Etoposide—prostate cancer	4.23e-05	0.000202	CcSEcCtD
Salbutamol—Connective tissue disorder—Doxorubicin—prostate cancer	4.23e-05	0.000202	CcSEcCtD
Salbutamol—Dyspnoea—Capecitabine—prostate cancer	4.23e-05	0.000202	CcSEcCtD
Salbutamol—Anaphylactic shock—Prednisone—prostate cancer	4.22e-05	0.000202	CcSEcCtD
Salbutamol—Oedema—Prednisone—prostate cancer	4.22e-05	0.000202	CcSEcCtD
Salbutamol—Fatigue—Docetaxel—prostate cancer	4.22e-05	0.000202	CcSEcCtD
Salbutamol—Angiopathy—Epirubicin—prostate cancer	4.22e-05	0.000202	CcSEcCtD
Salbutamol—Urethral disorder—Doxorubicin—prostate cancer	4.22e-05	0.000202	CcSEcCtD
Salbutamol—Nausea—Mitoxantrone—prostate cancer	4.21e-05	0.000201	CcSEcCtD
Salbutamol—Immune system disorder—Epirubicin—prostate cancer	4.2e-05	0.000201	CcSEcCtD
Salbutamol—Infection—Prednisone—prostate cancer	4.19e-05	0.000201	CcSEcCtD
Salbutamol—Mediastinal disorder—Epirubicin—prostate cancer	4.19e-05	0.0002	CcSEcCtD
Salbutamol—Pain—Docetaxel—prostate cancer	4.19e-05	0.0002	CcSEcCtD
Salbutamol—Constipation—Docetaxel—prostate cancer	4.19e-05	0.0002	CcSEcCtD
Salbutamol—Dyspepsia—Capecitabine—prostate cancer	4.17e-05	0.0002	CcSEcCtD
Salbutamol—Chills—Epirubicin—prostate cancer	4.17e-05	0.0002	CcSEcCtD
Salbutamol—Pruritus—Etoposide—prostate cancer	4.17e-05	0.000199	CcSEcCtD
Salbutamol—Shock—Prednisone—prostate cancer	4.15e-05	0.000199	CcSEcCtD
Salbutamol—Arrhythmia—Epirubicin—prostate cancer	4.15e-05	0.000199	CcSEcCtD
Salbutamol—Nervous system disorder—Prednisone—prostate cancer	4.14e-05	0.000198	CcSEcCtD
Salbutamol—Tachycardia—Prednisone—prostate cancer	4.12e-05	0.000197	CcSEcCtD
Salbutamol—Decreased appetite—Capecitabine—prostate cancer	4.12e-05	0.000197	CcSEcCtD
Salbutamol—Skin disorder—Prednisone—prostate cancer	4.1e-05	0.000196	CcSEcCtD
Salbutamol—Gastrointestinal disorder—Capecitabine—prostate cancer	4.09e-05	0.000196	CcSEcCtD
Salbutamol—Fatigue—Capecitabine—prostate cancer	4.09e-05	0.000196	CcSEcCtD
Salbutamol—Hyperhidrosis—Prednisone—prostate cancer	4.08e-05	0.000195	CcSEcCtD
Salbutamol—Mental disorder—Epirubicin—prostate cancer	4.07e-05	0.000195	CcSEcCtD
Salbutamol—Pain—Capecitabine—prostate cancer	4.05e-05	0.000194	CcSEcCtD
Salbutamol—Constipation—Capecitabine—prostate cancer	4.05e-05	0.000194	CcSEcCtD
Salbutamol—Malnutrition—Epirubicin—prostate cancer	4.05e-05	0.000194	CcSEcCtD
Salbutamol—Feeling abnormal—Docetaxel—prostate cancer	4.03e-05	0.000193	CcSEcCtD
Salbutamol—Diarrhoea—Etoposide—prostate cancer	4.03e-05	0.000193	CcSEcCtD
Salbutamol—Anorexia—Prednisone—prostate cancer	4.02e-05	0.000193	CcSEcCtD
Salbutamol—Tinnitus—Doxorubicin—prostate cancer	4.01e-05	0.000192	CcSEcCtD
Salbutamol—Gastrointestinal pain—Docetaxel—prostate cancer	4e-05	0.000192	CcSEcCtD
Salbutamol—Flushing—Doxorubicin—prostate cancer	3.99e-05	0.000191	CcSEcCtD
Salbutamol—Cardiac disorder—Doxorubicin—prostate cancer	3.99e-05	0.000191	CcSEcCtD
Salbutamol—Flatulence—Epirubicin—prostate cancer	3.99e-05	0.000191	CcSEcCtD
Salbutamol—Tension—Epirubicin—prostate cancer	3.97e-05	0.00019	CcSEcCtD
Salbutamol—Dysgeusia—Epirubicin—prostate cancer	3.96e-05	0.00019	CcSEcCtD
Salbutamol—Nervousness—Epirubicin—prostate cancer	3.93e-05	0.000188	CcSEcCtD
Salbutamol—Back pain—Epirubicin—prostate cancer	3.91e-05	0.000187	CcSEcCtD
Salbutamol—Feeling abnormal—Capecitabine—prostate cancer	3.91e-05	0.000187	CcSEcCtD
Salbutamol—Angiopathy—Doxorubicin—prostate cancer	3.9e-05	0.000187	CcSEcCtD
Salbutamol—Dizziness—Etoposide—prostate cancer	3.89e-05	0.000186	CcSEcCtD
Salbutamol—Muscle spasms—Epirubicin—prostate cancer	3.89e-05	0.000186	CcSEcCtD
Salbutamol—Immune system disorder—Doxorubicin—prostate cancer	3.88e-05	0.000186	CcSEcCtD
Salbutamol—Gastrointestinal pain—Capecitabine—prostate cancer	3.88e-05	0.000185	CcSEcCtD
Salbutamol—Mediastinal disorder—Doxorubicin—prostate cancer	3.88e-05	0.000185	CcSEcCtD
Salbutamol—Abdominal pain—Docetaxel—prostate cancer	3.87e-05	0.000185	CcSEcCtD
Salbutamol—Body temperature increased—Docetaxel—prostate cancer	3.87e-05	0.000185	CcSEcCtD
Salbutamol—Chills—Doxorubicin—prostate cancer	3.86e-05	0.000185	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Prednisone—prostate cancer	3.85e-05	0.000184	CcSEcCtD
Salbutamol—Arrhythmia—Doxorubicin—prostate cancer	3.84e-05	0.000184	CcSEcCtD
Salbutamol—Insomnia—Prednisone—prostate cancer	3.82e-05	0.000183	CcSEcCtD
Salbutamol—Paraesthesia—Prednisone—prostate cancer	3.79e-05	0.000181	CcSEcCtD
Salbutamol—Mental disorder—Doxorubicin—prostate cancer	3.77e-05	0.00018	CcSEcCtD
Salbutamol—Urticaria—Capecitabine—prostate cancer	3.76e-05	0.00018	CcSEcCtD
Salbutamol—Ill-defined disorder—Epirubicin—prostate cancer	3.75e-05	0.00018	CcSEcCtD
Salbutamol—Body temperature increased—Capecitabine—prostate cancer	3.75e-05	0.000179	CcSEcCtD
Salbutamol—Abdominal pain—Capecitabine—prostate cancer	3.75e-05	0.000179	CcSEcCtD
Salbutamol—Vomiting—Etoposide—prostate cancer	3.74e-05	0.000179	CcSEcCtD
Salbutamol—Malnutrition—Doxorubicin—prostate cancer	3.74e-05	0.000179	CcSEcCtD
Salbutamol—Agitation—Epirubicin—prostate cancer	3.72e-05	0.000178	CcSEcCtD
Salbutamol—Dyspepsia—Prednisone—prostate cancer	3.72e-05	0.000178	CcSEcCtD
Salbutamol—Rash—Etoposide—prostate cancer	3.71e-05	0.000178	CcSEcCtD
Salbutamol—Dermatitis—Etoposide—prostate cancer	3.71e-05	0.000178	CcSEcCtD
Salbutamol—Headache—Etoposide—prostate cancer	3.69e-05	0.000177	CcSEcCtD
Salbutamol—Flatulence—Doxorubicin—prostate cancer	3.69e-05	0.000176	CcSEcCtD
Salbutamol—Tension—Doxorubicin—prostate cancer	3.67e-05	0.000176	CcSEcCtD
Salbutamol—Decreased appetite—Prednisone—prostate cancer	3.67e-05	0.000176	CcSEcCtD
Salbutamol—Dysgeusia—Doxorubicin—prostate cancer	3.67e-05	0.000175	CcSEcCtD
Salbutamol—Malaise—Epirubicin—prostate cancer	3.65e-05	0.000175	CcSEcCtD
Salbutamol—Fatigue—Prednisone—prostate cancer	3.64e-05	0.000174	CcSEcCtD
Salbutamol—Nervousness—Doxorubicin—prostate cancer	3.64e-05	0.000174	CcSEcCtD
Salbutamol—Vertigo—Epirubicin—prostate cancer	3.63e-05	0.000174	CcSEcCtD
Salbutamol—Syncope—Epirubicin—prostate cancer	3.63e-05	0.000174	CcSEcCtD
Salbutamol—Back pain—Doxorubicin—prostate cancer	3.62e-05	0.000173	CcSEcCtD
Salbutamol—Constipation—Prednisone—prostate cancer	3.61e-05	0.000173	CcSEcCtD
Salbutamol—Hypersensitivity—Docetaxel—prostate cancer	3.61e-05	0.000173	CcSEcCtD
Salbutamol—Muscle spasms—Doxorubicin—prostate cancer	3.6e-05	0.000172	CcSEcCtD
Salbutamol—Palpitations—Epirubicin—prostate cancer	3.57e-05	0.000171	CcSEcCtD
Salbutamol—Loss of consciousness—Epirubicin—prostate cancer	3.56e-05	0.00017	CcSEcCtD
Salbutamol—Cough—Epirubicin—prostate cancer	3.53e-05	0.000169	CcSEcCtD
Salbutamol—Asthenia—Docetaxel—prostate cancer	3.51e-05	0.000168	CcSEcCtD
Salbutamol—Nausea—Etoposide—prostate cancer	3.5e-05	0.000167	CcSEcCtD
Salbutamol—Hypertension—Epirubicin—prostate cancer	3.49e-05	0.000167	CcSEcCtD
Salbutamol—Hypersensitivity—Capecitabine—prostate cancer	3.49e-05	0.000167	CcSEcCtD
Salbutamol—Feeling abnormal—Prednisone—prostate cancer	3.48e-05	0.000166	CcSEcCtD
Salbutamol—Ill-defined disorder—Doxorubicin—prostate cancer	3.47e-05	0.000166	CcSEcCtD
Salbutamol—Pruritus—Docetaxel—prostate cancer	3.46e-05	0.000166	CcSEcCtD
Salbutamol—Gastrointestinal pain—Prednisone—prostate cancer	3.45e-05	0.000165	CcSEcCtD
Salbutamol—Chest pain—Epirubicin—prostate cancer	3.44e-05	0.000165	CcSEcCtD
Salbutamol—Arthralgia—Epirubicin—prostate cancer	3.44e-05	0.000165	CcSEcCtD
Salbutamol—Myalgia—Epirubicin—prostate cancer	3.44e-05	0.000165	CcSEcCtD
Salbutamol—Agitation—Doxorubicin—prostate cancer	3.44e-05	0.000165	CcSEcCtD
Salbutamol—Anxiety—Epirubicin—prostate cancer	3.43e-05	0.000164	CcSEcCtD
Salbutamol—Discomfort—Epirubicin—prostate cancer	3.4e-05	0.000163	CcSEcCtD
Salbutamol—Asthenia—Capecitabine—prostate cancer	3.4e-05	0.000163	CcSEcCtD
Salbutamol—Malaise—Doxorubicin—prostate cancer	3.38e-05	0.000162	CcSEcCtD
Salbutamol—Dry mouth—Epirubicin—prostate cancer	3.37e-05	0.000161	CcSEcCtD
Salbutamol—Vertigo—Doxorubicin—prostate cancer	3.36e-05	0.000161	CcSEcCtD
Salbutamol—Syncope—Doxorubicin—prostate cancer	3.36e-05	0.000161	CcSEcCtD
Salbutamol—Urticaria—Prednisone—prostate cancer	3.35e-05	0.00016	CcSEcCtD
Salbutamol—Pruritus—Capecitabine—prostate cancer	3.35e-05	0.00016	CcSEcCtD
Salbutamol—Diarrhoea—Docetaxel—prostate cancer	3.35e-05	0.00016	CcSEcCtD
Salbutamol—Abdominal pain—Prednisone—prostate cancer	3.34e-05	0.00016	CcSEcCtD
Salbutamol—Body temperature increased—Prednisone—prostate cancer	3.34e-05	0.00016	CcSEcCtD
Salbutamol—Palpitations—Doxorubicin—prostate cancer	3.31e-05	0.000158	CcSEcCtD
Salbutamol—Anaphylactic shock—Epirubicin—prostate cancer	3.3e-05	0.000158	CcSEcCtD
Salbutamol—Oedema—Epirubicin—prostate cancer	3.3e-05	0.000158	CcSEcCtD
Salbutamol—Loss of consciousness—Doxorubicin—prostate cancer	3.29e-05	0.000157	CcSEcCtD
Salbutamol—Infection—Epirubicin—prostate cancer	3.28e-05	0.000157	CcSEcCtD
Salbutamol—Cough—Doxorubicin—prostate cancer	3.27e-05	0.000156	CcSEcCtD
Salbutamol—Shock—Epirubicin—prostate cancer	3.25e-05	0.000155	CcSEcCtD
Salbutamol—Diarrhoea—Capecitabine—prostate cancer	3.24e-05	0.000155	CcSEcCtD
Salbutamol—Nervous system disorder—Epirubicin—prostate cancer	3.24e-05	0.000155	CcSEcCtD
Salbutamol—Dizziness—Docetaxel—prostate cancer	3.24e-05	0.000155	CcSEcCtD
Salbutamol—Hypertension—Doxorubicin—prostate cancer	3.23e-05	0.000155	CcSEcCtD
Salbutamol—Tachycardia—Epirubicin—prostate cancer	3.22e-05	0.000154	CcSEcCtD
Salbutamol—Skin disorder—Epirubicin—prostate cancer	3.21e-05	0.000153	CcSEcCtD
Salbutamol—Hyperhidrosis—Epirubicin—prostate cancer	3.19e-05	0.000153	CcSEcCtD
Salbutamol—Arthralgia—Doxorubicin—prostate cancer	3.19e-05	0.000152	CcSEcCtD
Salbutamol—Myalgia—Doxorubicin—prostate cancer	3.19e-05	0.000152	CcSEcCtD
Salbutamol—Chest pain—Doxorubicin—prostate cancer	3.19e-05	0.000152	CcSEcCtD
Salbutamol—Anxiety—Doxorubicin—prostate cancer	3.18e-05	0.000152	CcSEcCtD
Salbutamol—Discomfort—Doxorubicin—prostate cancer	3.15e-05	0.000151	CcSEcCtD
Salbutamol—Anorexia—Epirubicin—prostate cancer	3.15e-05	0.000151	CcSEcCtD
Salbutamol—Dizziness—Capecitabine—prostate cancer	3.13e-05	0.00015	CcSEcCtD
Salbutamol—Dry mouth—Doxorubicin—prostate cancer	3.12e-05	0.000149	CcSEcCtD
Salbutamol—Vomiting—Docetaxel—prostate cancer	3.11e-05	0.000149	CcSEcCtD
Salbutamol—Hypersensitivity—Prednisone—prostate cancer	3.11e-05	0.000149	CcSEcCtD
Salbutamol—Rash—Docetaxel—prostate cancer	3.09e-05	0.000148	CcSEcCtD
Salbutamol—Hypotension—Epirubicin—prostate cancer	3.09e-05	0.000148	CcSEcCtD
Salbutamol—Dermatitis—Docetaxel—prostate cancer	3.08e-05	0.000148	CcSEcCtD
Salbutamol—Headache—Docetaxel—prostate cancer	3.07e-05	0.000147	CcSEcCtD
Salbutamol—Anaphylactic shock—Doxorubicin—prostate cancer	3.05e-05	0.000146	CcSEcCtD
Salbutamol—Oedema—Doxorubicin—prostate cancer	3.05e-05	0.000146	CcSEcCtD
Salbutamol—Infection—Doxorubicin—prostate cancer	3.03e-05	0.000145	CcSEcCtD
Salbutamol—Asthenia—Prednisone—prostate cancer	3.03e-05	0.000145	CcSEcCtD
Salbutamol—Vomiting—Capecitabine—prostate cancer	3.01e-05	0.000144	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Epirubicin—prostate cancer	3.01e-05	0.000144	CcSEcCtD
Salbutamol—Shock—Doxorubicin—prostate cancer	3.01e-05	0.000144	CcSEcCtD
Salbutamol—Nervous system disorder—Doxorubicin—prostate cancer	3e-05	0.000143	CcSEcCtD
Salbutamol—Rash—Capecitabine—prostate cancer	2.99e-05	0.000143	CcSEcCtD
Salbutamol—Pruritus—Prednisone—prostate cancer	2.99e-05	0.000143	CcSEcCtD
Salbutamol—Insomnia—Epirubicin—prostate cancer	2.99e-05	0.000143	CcSEcCtD
Salbutamol—Dermatitis—Capecitabine—prostate cancer	2.99e-05	0.000143	CcSEcCtD
Salbutamol—Tachycardia—Doxorubicin—prostate cancer	2.98e-05	0.000143	CcSEcCtD
Salbutamol—Headache—Capecitabine—prostate cancer	2.97e-05	0.000142	CcSEcCtD
Salbutamol—Skin disorder—Doxorubicin—prostate cancer	2.97e-05	0.000142	CcSEcCtD
Salbutamol—Paraesthesia—Epirubicin—prostate cancer	2.96e-05	0.000142	CcSEcCtD
Salbutamol—Hyperhidrosis—Doxorubicin—prostate cancer	2.95e-05	0.000141	CcSEcCtD
Salbutamol—Dyspnoea—Epirubicin—prostate cancer	2.94e-05	0.000141	CcSEcCtD
Salbutamol—Somnolence—Epirubicin—prostate cancer	2.94e-05	0.00014	CcSEcCtD
Salbutamol—Anorexia—Doxorubicin—prostate cancer	2.91e-05	0.000139	CcSEcCtD
Salbutamol—Nausea—Docetaxel—prostate cancer	2.91e-05	0.000139	CcSEcCtD
Salbutamol—Dyspepsia—Epirubicin—prostate cancer	2.91e-05	0.000139	CcSEcCtD
Salbutamol—Diarrhoea—Prednisone—prostate cancer	2.89e-05	0.000138	CcSEcCtD
Salbutamol—Decreased appetite—Epirubicin—prostate cancer	2.87e-05	0.000137	CcSEcCtD
Salbutamol—Hypotension—Doxorubicin—prostate cancer	2.85e-05	0.000137	CcSEcCtD
Salbutamol—Gastrointestinal disorder—Epirubicin—prostate cancer	2.85e-05	0.000136	CcSEcCtD
Salbutamol—Fatigue—Epirubicin—prostate cancer	2.85e-05	0.000136	CcSEcCtD
Salbutamol—Constipation—Epirubicin—prostate cancer	2.82e-05	0.000135	CcSEcCtD
Salbutamol—Pain—Epirubicin—prostate cancer	2.82e-05	0.000135	CcSEcCtD
Salbutamol—Nausea—Capecitabine—prostate cancer	2.82e-05	0.000135	CcSEcCtD
Salbutamol—Dizziness—Prednisone—prostate cancer	2.79e-05	0.000134	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Doxorubicin—prostate cancer	2.78e-05	0.000133	CcSEcCtD
Salbutamol—Insomnia—Doxorubicin—prostate cancer	2.76e-05	0.000132	CcSEcCtD
Salbutamol—Paraesthesia—Doxorubicin—prostate cancer	2.74e-05	0.000131	CcSEcCtD
Salbutamol—Dyspnoea—Doxorubicin—prostate cancer	2.72e-05	0.00013	CcSEcCtD
Salbutamol—Feeling abnormal—Epirubicin—prostate cancer	2.72e-05	0.00013	CcSEcCtD
Salbutamol—Somnolence—Doxorubicin—prostate cancer	2.72e-05	0.00013	CcSEcCtD
Salbutamol—Gastrointestinal pain—Epirubicin—prostate cancer	2.7e-05	0.000129	CcSEcCtD
Salbutamol—Dyspepsia—Doxorubicin—prostate cancer	2.69e-05	0.000129	CcSEcCtD
Salbutamol—Vomiting—Prednisone—prostate cancer	2.68e-05	0.000128	CcSEcCtD
Salbutamol—Rash—Prednisone—prostate cancer	2.66e-05	0.000127	CcSEcCtD
Salbutamol—Dermatitis—Prednisone—prostate cancer	2.66e-05	0.000127	CcSEcCtD
Salbutamol—Decreased appetite—Doxorubicin—prostate cancer	2.66e-05	0.000127	CcSEcCtD
Salbutamol—Headache—Prednisone—prostate cancer	2.64e-05	0.000127	CcSEcCtD
Salbutamol—Gastrointestinal disorder—Doxorubicin—prostate cancer	2.64e-05	0.000126	CcSEcCtD
Salbutamol—Fatigue—Doxorubicin—prostate cancer	2.63e-05	0.000126	CcSEcCtD
Salbutamol—Urticaria—Epirubicin—prostate cancer	2.62e-05	0.000126	CcSEcCtD
Salbutamol—Pain—Doxorubicin—prostate cancer	2.61e-05	0.000125	CcSEcCtD
Salbutamol—Constipation—Doxorubicin—prostate cancer	2.61e-05	0.000125	CcSEcCtD
Salbutamol—Abdominal pain—Epirubicin—prostate cancer	2.61e-05	0.000125	CcSEcCtD
Salbutamol—Body temperature increased—Epirubicin—prostate cancer	2.61e-05	0.000125	CcSEcCtD
Salbutamol—Feeling abnormal—Doxorubicin—prostate cancer	2.52e-05	0.00012	CcSEcCtD
Salbutamol—Nausea—Prednisone—prostate cancer	2.51e-05	0.00012	CcSEcCtD
Salbutamol—Gastrointestinal pain—Doxorubicin—prostate cancer	2.5e-05	0.00012	CcSEcCtD
Salbutamol—Hypersensitivity—Epirubicin—prostate cancer	2.43e-05	0.000116	CcSEcCtD
Salbutamol—Urticaria—Doxorubicin—prostate cancer	2.43e-05	0.000116	CcSEcCtD
Salbutamol—Body temperature increased—Doxorubicin—prostate cancer	2.41e-05	0.000116	CcSEcCtD
Salbutamol—Abdominal pain—Doxorubicin—prostate cancer	2.41e-05	0.000116	CcSEcCtD
Salbutamol—Asthenia—Epirubicin—prostate cancer	2.37e-05	0.000113	CcSEcCtD
Salbutamol—Pruritus—Epirubicin—prostate cancer	2.34e-05	0.000112	CcSEcCtD
Salbutamol—Diarrhoea—Epirubicin—prostate cancer	2.26e-05	0.000108	CcSEcCtD
Salbutamol—Hypersensitivity—Doxorubicin—prostate cancer	2.25e-05	0.000108	CcSEcCtD
Salbutamol—Asthenia—Doxorubicin—prostate cancer	2.19e-05	0.000105	CcSEcCtD
Salbutamol—Dizziness—Epirubicin—prostate cancer	2.18e-05	0.000104	CcSEcCtD
Salbutamol—Pruritus—Doxorubicin—prostate cancer	2.16e-05	0.000103	CcSEcCtD
Salbutamol—Vomiting—Epirubicin—prostate cancer	2.1e-05	0.0001	CcSEcCtD
Salbutamol—Diarrhoea—Doxorubicin—prostate cancer	2.09e-05	0.0001	CcSEcCtD
Salbutamol—Rash—Epirubicin—prostate cancer	2.08e-05	9.96e-05	CcSEcCtD
Salbutamol—Dermatitis—Epirubicin—prostate cancer	2.08e-05	9.95e-05	CcSEcCtD
Salbutamol—Headache—Epirubicin—prostate cancer	2.07e-05	9.9e-05	CcSEcCtD
Salbutamol—Dizziness—Doxorubicin—prostate cancer	2.02e-05	9.67e-05	CcSEcCtD
Salbutamol—Nausea—Epirubicin—prostate cancer	1.96e-05	9.38e-05	CcSEcCtD
Salbutamol—Vomiting—Doxorubicin—prostate cancer	1.94e-05	9.29e-05	CcSEcCtD
Salbutamol—Rash—Doxorubicin—prostate cancer	1.93e-05	9.22e-05	CcSEcCtD
Salbutamol—Dermatitis—Doxorubicin—prostate cancer	1.92e-05	9.21e-05	CcSEcCtD
Salbutamol—Headache—Doxorubicin—prostate cancer	1.91e-05	9.16e-05	CcSEcCtD
Salbutamol—Nausea—Doxorubicin—prostate cancer	1.81e-05	8.68e-05	CcSEcCtD
Salbutamol—CYP3A4—Metabolism—DEGS1—prostate cancer	1.17e-05	0.000312	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—NAT1—prostate cancer	1.17e-05	0.000312	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—ANXA1—prostate cancer	1.16e-05	0.000311	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PRKCZ—prostate cancer	1.14e-05	0.000305	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—PIK3CG—prostate cancer	1.14e-05	0.000305	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—FGFR4—prostate cancer	1.13e-05	0.000301	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PARP1—prostate cancer	1.13e-05	0.000301	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—PIK3CG—prostate cancer	1.12e-05	0.000298	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CALCA—prostate cancer	1.11e-05	0.000298	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—HSD17B1—prostate cancer	1.11e-05	0.000298	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—FGFR4—prostate cancer	1.1e-05	0.000295	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PARP1—prostate cancer	1.1e-05	0.000295	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CALCA—prostate cancer	1.09e-05	0.000291	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CXCL12—prostate cancer	1.09e-05	0.000291	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CXCL12—prostate cancer	1.06e-05	0.000285	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—PIK3CG—prostate cancer	1.04e-05	0.000277	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CASP9—prostate cancer	1.02e-05	0.000274	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—PIK3CG—prostate cancer	1.01e-05	0.000271	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—PIK3CD—prostate cancer	1e-05	0.000268	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CASP9—prostate cancer	1e-05	0.000268	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PRKCQ—prostate cancer	9.92e-06	0.000265	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—NGFR—prostate cancer	9.92e-06	0.000265	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—HPGD—prostate cancer	9.91e-06	0.000265	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—B4GALT4—prostate cancer	9.91e-06	0.000265	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—PIK3CD—prostate cancer	9.8e-06	0.000262	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—MAP3K7—prostate cancer	9.8e-06	0.000262	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PRKCQ—prostate cancer	9.7e-06	0.00026	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—NGFR—prostate cancer	9.7e-06	0.00026	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—MAP3K7—prostate cancer	9.59e-06	0.000257	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—FGF10—prostate cancer	9.42e-06	0.000252	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—ADRB2—prostate cancer	9.32e-06	0.00025	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—TNFRSF21—prostate cancer	9.32e-06	0.000249	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—FGF10—prostate cancer	9.22e-06	0.000247	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—JAK2—prostate cancer	9.2e-06	0.000246	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—MAP2K1—prostate cancer	9.16e-06	0.000245	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—PIK3CD—prostate cancer	9.1e-06	0.000244	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—VAV3—prostate cancer	9.09e-06	0.000243	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CYP7B1—prostate cancer	9.07e-06	0.000243	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—MTAP—prostate cancer	9.07e-06	0.000243	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—JAK2—prostate cancer	9e-06	0.000241	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—TGFBR2—prostate cancer	8.96e-06	0.00024	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—MAP2K1—prostate cancer	8.96e-06	0.00024	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—PIK3CD—prostate cancer	8.9e-06	0.000238	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—VAV3—prostate cancer	8.89e-06	0.000238	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—SULT1E1—prostate cancer	8.83e-06	0.000236	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—SRD5A1—prostate cancer	8.83e-06	0.000236	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—ITPR1—prostate cancer	8.82e-06	0.000236	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—TGFBR2—prostate cancer	8.77e-06	0.000235	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—PIK3CB—prostate cancer	8.74e-06	0.000234	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—ITPR1—prostate cancer	8.63e-06	0.000231	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—PIK3CB—prostate cancer	8.55e-06	0.000229	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—IGF1R—prostate cancer	8.43e-06	0.000226	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ACSL4—prostate cancer	8.43e-06	0.000226	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—HSD17B3—prostate cancer	8.43e-06	0.000226	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—CXCL8—prostate cancer	8.39e-06	0.000225	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—JAK2—prostate cancer	8.35e-06	0.000224	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—IGF1R—prostate cancer	8.25e-06	0.000221	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—CXCL8—prostate cancer	8.21e-06	0.00022	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—JAK2—prostate cancer	8.17e-06	0.000219	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—LPL—prostate cancer	8.08e-06	0.000216	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—UMPS—prostate cancer	8.08e-06	0.000216	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PHGDH—prostate cancer	8.08e-06	0.000216	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ARG2—prostate cancer	8.08e-06	0.000216	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—IL2—prostate cancer	8.02e-06	0.000215	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PDGFRB—prostate cancer	8.01e-06	0.000214	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—PIK3CB—prostate cancer	7.93e-06	0.000212	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—LDHB—prostate cancer	7.92e-06	0.000212	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—LPL—prostate cancer	7.91e-06	0.000212	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—IL2—prostate cancer	7.85e-06	0.00021	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PDGFRB—prostate cancer	7.84e-06	0.00021	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—ITGB3—prostate cancer	7.81e-06	0.000209	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CYP3A5—prostate cancer	7.78e-06	0.000208	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—PIK3CB—prostate cancer	7.76e-06	0.000208	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—ITGB3—prostate cancer	7.64e-06	0.000204	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—CXCL8—prostate cancer	7.62e-06	0.000204	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—ERBB3—prostate cancer	7.57e-06	0.000203	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—FGFR2—prostate cancer	7.56e-06	0.000202	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PDHA1—prostate cancer	7.51e-06	0.000201	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—TCN2—prostate cancer	7.51e-06	0.000201	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—UCP3—prostate cancer	7.51e-06	0.000201	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GSTA3—prostate cancer	7.51e-06	0.000201	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—CXCL8—prostate cancer	7.46e-06	0.0002	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—ERBB3—prostate cancer	7.41e-06	0.000198	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—FGFR2—prostate cancer	7.4e-06	0.000198	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—IL2—prostate cancer	7.29e-06	0.000195	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—TERT—prostate cancer	7.26e-06	0.000194	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—HSD3B1—prostate cancer	7.17e-06	0.000192	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—SLC22A3—prostate cancer	7.17e-06	0.000192	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—IL2—prostate cancer	7.13e-06	0.000191	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—TERT—prostate cancer	7.1e-06	0.00019	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—HIF1A—prostate cancer	6.94e-06	0.000186	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—TBXAS1—prostate cancer	6.87e-06	0.000184	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GSTA4—prostate cancer	6.87e-06	0.000184	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—HIF1A—prostate cancer	6.79e-06	0.000182	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—LEP—prostate cancer	6.78e-06	0.000181	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CAV1—prostate cancer	6.71e-06	0.00018	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GSTA2—prostate cancer	6.7e-06	0.000179	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—KDR—prostate cancer	6.64e-06	0.000178	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—LEP—prostate cancer	6.63e-06	0.000177	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ABCG5—prostate cancer	6.61e-06	0.000177	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—SULT1A1—prostate cancer	6.61e-06	0.000177	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CAV1—prostate cancer	6.57e-06	0.000176	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—KDR—prostate cancer	6.49e-06	0.000174	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—ESR1—prostate cancer	6.47e-06	0.000173	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GSTA1—prostate cancer	6.46e-06	0.000173	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GSTO1—prostate cancer	6.39e-06	0.000171	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—NAT2—prostate cancer	6.39e-06	0.000171	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—HSD3B2—prostate cancer	6.39e-06	0.000171	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—ESR1—prostate cancer	6.33e-06	0.000169	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—BAD—prostate cancer	6.31e-06	0.000169	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—BAD—prostate cancer	6.18e-06	0.000165	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PLCB2—prostate cancer	6.12e-06	0.000164	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—LRP2—prostate cancer	6.12e-06	0.000164	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CYP2C18—prostate cancer	6.12e-06	0.000164	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PIK3CG—prostate cancer	6.12e-06	0.000164	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—APC—prostate cancer	6.12e-06	0.000164	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—EGF—prostate cancer	6.05e-06	0.000162	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—IRS1—prostate cancer	6.05e-06	0.000162	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—P4HB—prostate cancer	6.01e-06	0.000161	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PIK3CG—prostate cancer	5.98e-06	0.00016	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—APC—prostate cancer	5.98e-06	0.00016	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—IRS1—prostate cancer	5.91e-06	0.000158	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—EGF—prostate cancer	5.91e-06	0.000158	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—GSK3B—prostate cancer	5.87e-06	0.000157	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—SLC22A1—prostate cancer	5.84e-06	0.000156	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—INS—prostate cancer	5.79e-06	0.000155	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—GSK3B—prostate cancer	5.74e-06	0.000154	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—SULT2A1—prostate cancer	5.69e-06	0.000152	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CREBBP—prostate cancer	5.67e-06	0.000152	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—INS—prostate cancer	5.66e-06	0.000152	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—MED12—prostate cancer	5.6e-06	0.00015	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—IGF1—prostate cancer	5.6e-06	0.00015	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—EGFR—prostate cancer	5.57e-06	0.000149	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GNG5—prostate cancer	5.56e-06	0.000149	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CREBBP—prostate cancer	5.55e-06	0.000148	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—IGF1—prostate cancer	5.48e-06	0.000147	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—EGFR—prostate cancer	5.45e-06	0.000146	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—MAP2K1—prostate cancer	5.41e-06	0.000145	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PIK3CD—prostate cancer	5.38e-06	0.000144	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—NCOA3—prostate cancer	5.35e-06	0.000143	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—PIK3CA—prostate cancer	5.33e-06	0.000143	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—SERPINE1—prostate cancer	5.32e-06	0.000142	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—MAP2K1—prostate cancer	5.29e-06	0.000142	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—KRAS—prostate cancer	5.26e-06	0.000141	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PIK3CD—prostate cancer	5.26e-06	0.000141	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—PIK3CA—prostate cancer	5.21e-06	0.000139	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—SERPINE1—prostate cancer	5.2e-06	0.000139	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—KRAS—prostate cancer	5.15e-06	0.000138	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—FGF2—prostate cancer	5.15e-06	0.000138	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—HPGDS—prostate cancer	5.11e-06	0.000137	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—NOS3—prostate cancer	5.08e-06	0.000136	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CYP2C19—prostate cancer	5.07e-06	0.000136	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—FGF2—prostate cancer	5.04e-06	0.000135	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—NOS3—prostate cancer	4.97e-06	0.000133	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ACHE—prostate cancer	4.95e-06	0.000133	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GSTT1—prostate cancer	4.95e-06	0.000133	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—JAK2—prostate cancer	4.93e-06	0.000132	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CYP2A6—prostate cancer	4.9e-06	0.000131	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—PIK3CA—prostate cancer	4.84e-06	0.000129	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—JAK2—prostate cancer	4.83e-06	0.000129	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—MDM2—prostate cancer	4.82e-06	0.000129	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—AKR1C3—prostate cancer	4.76e-06	0.000127	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—ERBB2—prostate cancer	4.75e-06	0.000127	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PRKACB—prostate cancer	4.74e-06	0.000127	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—PIK3CA—prostate cancer	4.73e-06	0.000127	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—MDM2—prostate cancer	4.71e-06	0.000126	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CYP17A1—prostate cancer	4.69e-06	0.000125	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PIK3CB—prostate cancer	4.69e-06	0.000125	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—ERBB2—prostate cancer	4.65e-06	0.000124	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PIK3CB—prostate cancer	4.58e-06	0.000123	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CXCL8—prostate cancer	4.5e-06	0.000121	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—NCOA2—prostate cancer	4.47e-06	0.00012	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CXCL8—prostate cancer	4.41e-06	0.000118	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CDKN1B—prostate cancer	4.4e-06	0.000118	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—AKT1—prostate cancer	4.35e-06	0.000116	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CASP3—prostate cancer	4.31e-06	0.000115	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—IL2—prostate cancer	4.3e-06	0.000115	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CDKN1B—prostate cancer	4.3e-06	0.000115	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—IL6—prostate cancer	4.28e-06	0.000115	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—SLC5A5—prostate cancer	4.26e-06	0.000114	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—AKT1—prostate cancer	4.26e-06	0.000114	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CASP3—prostate cancer	4.22e-06	0.000113	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—IL2—prostate cancer	4.21e-06	0.000113	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CCND1—prostate cancer	4.2e-06	0.000112	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—IL6—prostate cancer	4.19e-06	0.000112	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CYP2E1—prostate cancer	4.16e-06	0.000111	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CTNNB1—prostate cancer	4.15e-06	0.000111	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—NQO1—prostate cancer	4.12e-06	0.00011	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CCND1—prostate cancer	4.1e-06	0.00011	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—MMP9—prostate cancer	4.07e-06	0.000109	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CTNNB1—prostate cancer	4.06e-06	0.000109	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CDKN1A—prostate cancer	4.06e-06	0.000109	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—TH—prostate cancer	4.06e-06	0.000109	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PTEN—prostate cancer	4.05e-06	0.000108	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—MMP9—prostate cancer	3.98e-06	0.000107	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CDKN1A—prostate cancer	3.97e-06	0.000106	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PTEN—prostate cancer	3.96e-06	0.000106	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—AKT1—prostate cancer	3.95e-06	0.000106	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CYP1B1—prostate cancer	3.95e-06	0.000106	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—AKT1—prostate cancer	3.86e-06	0.000103	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—EP300—prostate cancer	3.86e-06	0.000103	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GGT1—prostate cancer	3.82e-06	0.000102	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—EP300—prostate cancer	3.78e-06	0.000101	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—NCOA1—prostate cancer	3.76e-06	0.000101	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—SRC—prostate cancer	3.76e-06	0.000101	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CYP19A1—prostate cancer	3.71e-06	9.93e-05	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—SRC—prostate cancer	3.67e-06	9.83e-05	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—VEGFA—prostate cancer	3.66e-06	9.79e-05	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—STAT3—prostate cancer	3.62e-06	9.69e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—RXRA—prostate cancer	3.58e-06	9.58e-05	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—VEGFA—prostate cancer	3.58e-06	9.58e-05	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—STAT3—prostate cancer	3.54e-06	9.48e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—COMT—prostate cancer	3.45e-06	9.23e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GSTP1—prostate cancer	3.43e-06	9.19e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ITPR1—prostate cancer	3.38e-06	9.04e-05	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—MYC—prostate cancer	3.37e-06	9.01e-05	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—TGFB1—prostate cancer	3.36e-06	8.99e-05	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—MYC—prostate cancer	3.29e-06	8.81e-05	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—EGFR—prostate cancer	3.29e-06	8.81e-05	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—TGFB1—prostate cancer	3.28e-06	8.79e-05	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—EGFR—prostate cancer	3.22e-06	8.62e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—TYMS—prostate cancer	3.19e-06	8.54e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GSTM1—prostate cancer	3.15e-06	8.44e-05	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—KRAS—prostate cancer	3.11e-06	8.32e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—LPL—prostate cancer	3.1e-06	8.29e-05	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—KRAS—prostate cancer	3.04e-06	8.14e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CYP1A1—prostate cancer	2.99e-06	8e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ERCC2—prostate cancer	2.97e-06	7.94e-05	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PIK3CA—prostate cancer	2.86e-06	7.65e-05	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PIK3CA—prostate cancer	2.79e-06	7.48e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—MTHFR—prostate cancer	2.79e-06	7.46e-05	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—TP53—prostate cancer	2.76e-06	7.4e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PPARA—prostate cancer	2.74e-06	7.32e-05	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—TP53—prostate cancer	2.7e-06	7.24e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CAV1—prostate cancer	2.57e-06	6.88e-05	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—IL6—prostate cancer	2.53e-06	6.77e-05	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—IL6—prostate cancer	2.47e-06	6.62e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PIK3CG—prostate cancer	2.34e-06	6.27e-05	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—AKT1—prostate cancer	2.33e-06	6.25e-05	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—AKT1—prostate cancer	2.28e-06	6.11e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—INS—prostate cancer	2.22e-06	5.94e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CREBBP—prostate cancer	2.17e-06	5.81e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PIK3CD—prostate cancer	2.06e-06	5.51e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—NOS3—prostate cancer	1.94e-06	5.2e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PIK3CB—prostate cancer	1.79e-06	4.8e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PTGS2—prostate cancer	1.78e-06	4.76e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PTEN—prostate cancer	1.55e-06	4.15e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—EP300—prostate cancer	1.48e-06	3.96e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PIK3CA—prostate cancer	1.09e-06	2.93e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—AKT1—prostate cancer	8.94e-07	2.39e-05	CbGpPWpGaD
